Article
type: Class

Document
type: Class

Anualidad
type: Class

Academic Article
type: Class

Information Content Entity
type: Class

Continuant
type: Class

Entity
type: Class

Generically Dependent Continuant
type: Class

2015
type: Class

individual
type: Document
rights: termsOfUse
date: 2026-08-29T18:39:01
publisher: Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02
label: RDF description of Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02 - http://research.umh.es/vivo/pub/articulo/161695

Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02
type: Document
page start: 319
most specific type: Academic Article
type: Information Content Entity
ARG_2000028: 161695 vcard
type: Article
most specific type: 2015
type: Generically Dependent Continuant
date time value: 161695 pubdate
page end: 324
type: Thing
type: 2015
type: Entity
type: Anualidad
related by: Autor:153379-Artículo:161695
type: Academic Article
type: Continuant
has publication venue: CANCER CHEMOTHERAPY AND PHARMACOLOGY

Autor:153379-Artículo:161695
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02

CANCER CHEMOTHERAPY AND PHARMACOLOGY
type: Entity
type: Collection
type: Continuant
type: Periodical
publication venue for: Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02
type: Journal
type: Information Content Entity
type: Thing
type: Generically Dependent Continuant